CTU COVID Testing Supplement

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2020
  • Known Financial Commitments (USD)

    $599,941
  • Funder

    National Institutes of Health (NIH)
  • Principle Investigator

    Pending
  • Research Location

    United States of America, Americas
  • Lead Research Institution

    EMORY UNIVERSITY
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    Gender

  • Study Subject

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Emory-CDC Clinical Trials Unit-Supplement for COVID-19 testingProject Summary/AbstractThe emerging COVID-19 pandemic, caused by the SARS-Co-V-2 coronavirus has already caused over 1.3million infections and over 80,000 deaths in the US as of May 13, 2020 (1). In the absence of effectivetherapies or a vaccine, non-pharmacologic measures such as social distancing, face masks and lockdownshave been implemented for prevention of COVID-19 infection which has helped to decrease the spread.Additional critical measures to control the pandemic include identification and isolation of infected individualsand contact tracing which requires scaling up of testing for all people. As of May 13, 2020, the US has beenable to perform ~ 9 million tests, or around 29,000 tests/million population. While this is a large number and, infact, more tests performed than any other country in the world, it is still not sufficient. Several investigatorssuggest that 3 - 4 million tests/week are needed in order to test ~ 1% of the US population.Atlanta, Georgia has not been spared by the COVID-19 pandemic. While these is no data available for City ofAtlanta, the 5 counties that form the Atlanta metropolitan area (Fulton, DeKalb, Gwinnett, Clayton and Cobb)have reported 11,771 cases which represents 34% of the total cases reported in the State of Georgia (2). Thecharacteristics and clinical outcomes of hospitalized patients with COVID-19 in Georgia have been recentlydescribed (3). Among 305 patients, the median age was 60 years with 29% of the patients under the age of 50.Also, 83% were African American and although co-morbid conditions such as diabetes, obesity andhypertension were common, 1 in 4 patients admitted did not have any high-risk conditions. In a study amongCOVID-19 patients in three hospitals where Emory University faculty provide medical care, 20 of 530 personshad HIV co-infection. Median age was 57 years, most had controlled HIV and comorbid condition such ashypertension and diabetes.The Emory-CDC HIV Clinical Trials Unit has two Clinical Research Sites in Atlanta, the Hope Clinic of theEmory Vaccine Center and the Ponce de Leon Clinic. Both sites offer great opportunities to expand testing,not only to their existing patient populations but also to the neighboring communities. In this application wepropose to use the existing infrastructure for research and will add expanded facilities for COVID-19 testing.Since testing for COVID-19 must incorporate safety measures for the staff, we plan to develop expandedfacilities including temporary tents to accommodate potential drive through scenarios, and/or a mobile healthclinic.